Transfection, the introduction of nucleic acid into mammalian cells, is a powerful technique used to study in vivo gene function and regulation. The Cytofect™ Fibroblast Transfection kit is a plasmid DNA delivery system specifically optimized to deliver DNA into a wide variety of fibroblasts. This kit contains Cytofect-2, Enhancer and Media for transfection and culturing cells. Peptide Enhancer complexes with DNA and Cytofect-2 and escorts the transfection complex to the nucleus. This results in high transfection efficiency and viability for these traditionally hard-to-transfect primary fibroblasts.
#Wells / Rxns
96 / 1000
24 / 250
12 / 125
The Kit contains all necessary reagents, media and optimized protocols to carry out successful transfection of primary fibroblasts with high efficiency (30%-70%) and viability (90%-95%).
Products are for research use only. They are not intended for human, animal, or diagnostic applications. TR2 and PE are manufactured by Targeting Systems.
Peptide Enhancer (PE)
Antibiotics-Free Growth Medium
Designed to improve transfection efficiency and cell viability, Cytofect is a plasmid DNA delivery system containing Cytofect-2, Enhancer and Media for transfecting and culturing cells. The Enhancer is an endosomolytic peptide that complexes with DNA and Cytofect-2, then escorts the transfection complex to the nucleus. The results are high transfection efficiency and viability for traditionally hard-to-transfect cells.
|Cytofect™ Fibroblast Transfection Kit: 250 x 24-Well Rxns||Size: 1 Kit||CAT.#: TF103K||Price: $404.00|
|Cytofect™ Fibroblast Transfection Kit: 25 x 24-Well Rxns||Size: 1 Sample Kit||CAT.#: TF103KS||Price: $54.00|
|Cytofect-1 (CF1): Store at -20°C||Size: 250 ul||CAT.#: 051-250||Price: $152.00|
|Cytofect-1 (CF1): Store at -20°C||Size: 500 ul||CAT.#: 051-500||Price: $246.00|
|Cytofect-2 (CF2) : Store at 4°C||Size: 250 ul||CAT.#: 052-250||Price: $152.00|
|Cytofect-2 (CF2) : Store at 4°C||Size: 500 ul||CAT.#: 052-500||Price: $246.00|
|Peptide Enhancer (PE): Store at 4°C||Size: 250 ul||CAT.#: 053-250||Price: $123.00|
|Peptide Enhancer (PE): Store at 4°C||Size: 500 ul||CAT.#: 053-500||Price: $205.00|
|Viral Enhancer (VE): Store at -20°C||Size: 250 ul||CAT.#: 054-250||Price: $123.00|
|Viral Enhancer (VE): Store at -20°C||Size: 500 ul||CAT.#: 054-500||Price: $205.00|
Sahoo, S., D. Meijles, I. Ghouleh, M. Tandon, E. Cifuentes-Pagano, J. Sembrat, M. Rojas, E. Goncharova and P. Pagano. 2016. MEF2C-MYOCD and Leiomodin1 Suppression by miRNA-214 Promotes Smooth Muscle Cell Phenotype Switching in Pulmonary Arterial Hypertension. PLoS ONE, dx.doi.org/10.1371/journal.pone.0153780.
Dokun, A., L. Chen, M. Okutsu, C. Farber, S. Hazarika, W. Jones, D. Craig, D. Marchuk, J. Lye, S. Shan, and B. Annex. 2015. ADAM12: A Genetic Modifier of Pre-clinical Peripheral Arterial Disease. Am J Physiol, DOI: 10.1152/ajpheart.00803.2014.
Zelko, I., and R. Folz. 2015. Regulation of Oxidative Stress in Pulmonary Artery Endothelium: Modulation of EC-SOD and NOX4 Expression Using HDAC Class I Inhibitors. Am J Respir Cell Mol Biol, DOI: 10.1165/rcmb.2014-0260OC.
Chen, Z., T.C. Lai, Y.H. Jan, F.M. Lin, W.C. Wang, H. Xiao, Y.T. Wang, W. Sun, X. Cui, Y.S. Li, T. Fang, H. Zhao, C. Padmanabhan, R. Sun, D.L. Wang, H. Jin, G.Y. Chau, H.D. Huang, M. Hsiao, and J.Y.J. Shyy. 2013. Hypoxia-responsive miRNAs target argonaute 1 to promote angiogenesis. The Journal of Clinical Investigation. 123:1057-1067.
He, M., X. Liang, L. He, W. Wen, S. Zhao, L. Wen, Y. Liu, J.Y.J. Shyy, and Z. Yuan. 2013. Endothelial dysfunction in rheumatoid arthritis: the role of monocyte chemotactic protein-1-induced protein. Arteriosclerosis, Thrombosis, and Vascular Biology. 33:1384-1391.
Yan, Y., X. Li, K. Kover, M. Clements, and P. Ye. 2013. CREB participates in the IGF‐I‐stimulation cyclin D1 transcription. Developmental Neurobiology. 73:559-570.
Jeon, Y.J., M.G. Jo, H.M. Yoo, S.H. Hong, J.M. Park, S.H. Ka, K.H. Oh, J.H. Seol, Y.K. Jung, and C.H. Chung. 2012. Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. The Journal of Clinical Investigation. 122:2622-2636.